PHIO: Phio Pharmaceuticals Corp Financial Statements
Balance sheet, income statement, and cash flow statements for Phio Pharmaceuticals Corp (PHIO).
$1.90M Market Cap.
PHIO Market Cap. (MRY)
PHIO Shares Outstanding (MRY)
PHIO Assets (MRY)
Total Assets
$5.74M
Total Liabilities
$1.01M
Total Investments
$0
PHIO Income (MRY)
Revenue
$0
Net Income
-$7.15M
Operating Expense
$7.39M
PHIO Cash Flow (MRY)
CF Operations
-$7.11M
CF Investing
$8.00K
CF Financing
$4.00M
PHIO Balance Sheet (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|
Total Assets | $5,738,000 (-38.72%) | $9,364,000 (-26.92%) | $12,814,000 (-49.09%) | $25,170,000 (59.92%) |
Assets Current | $5,736,000 (-38.47%) | $9,322,000 (-25.10%) | $12,446,000 (-49.67%) | $24,727,000 (63.06%) |
Assets Non-Current | $2,000 (-95.24%) | $42,000 (-88.59%) | $368,000 (-16.93%) | $443,000 (-22.96%) |
Goodwill & Intangible Assets | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Shareholders Equity | $4,723,000 (-38.90%) | $7,730,000 (-28.68%) | $10,838,000 (-50.58%) | $21,932,000 (68.49%) |
Property Plant & Equipment Net | $2,000 (-94.87%) | $39,000 (-88.66%) | $344,000 (-17.31%) | $416,000 (-25.31%) |
Cash & Equivalents | $5,382,000 (-36.61%) | $8,490,000 (-28.24%) | $11,831,000 (-50.92%) | $24,107,000 (68.65%) |
Accumulated Other Comprehensive Income | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Deferred Revenue | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Total Investments | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Investments Current | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Investments Non-Current | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Inventory | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Trade & Non-Trade Receivables | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Trade & Non-Trade Payables | $253,000 (-61.49%) | $657,000 (-15.66%) | $779,000 (175.27%) | $283,000 (-61.13%) |
Accumulated Retained Earnings (Deficit) | -$146,356,000 (-5.14%) | -$139,206,000 (-8.43%) | -$128,380,000 (-9.82%) | -$116,900,000 (-12.82%) |
Tax Assets | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Tax Liabilities | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Total Debt | $0 (0%) | $35,000 (-79.41%) | $170,000 (-42.37%) | $295,000 (-54.05%) |
Debt Current | $0 (0%) | $35,000 (-74.07%) | $135,000 (8.00%) | $125,000 (7.76%) |
Debt Non-Current | $0 (0%) | $0 (0%) | $35,000 (-79.41%) | $170,000 (-67.68%) |
Total Liabilities | $1,015,000 (-37.88%) | $1,634,000 (-17.22%) | $1,974,000 (-39.04%) | $3,238,000 (18.96%) |
Liabilities Current | $1,015,000 (-37.88%) | $1,634,000 (-15.73%) | $1,939,000 (-36.80%) | $3,068,000 (39.71%) |
Liabilities Non-Current | $0 (0%) | $0 (0%) | $35,000 (-79.41%) | $170,000 (-67.68%) |
PHIO Income Statement (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|
Revenues | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Cost of Revenue | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Selling General & Administrative Expense | $3,744,000 (-14.25%) | $4,366,000 (-1.89%) | $4,450,000 (-3.78%) | $4,625,000 (-8.90%) |
Research & Development Expense | $3,643,000 (-42.47%) | $6,332,000 (-9.70%) | $7,012,000 (-21.09%) | $8,886,000 (139.13%) |
Operating Expenses | $7,387,000 (-31.75%) | $10,824,000 (-5.57%) | $11,462,000 (-15.17%) | $13,511,000 (53.66%) |
Interest Expense | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Income Tax Expense | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Net Loss Income from Discontinued Operations | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Consolidated Income | -$7,150,000 (33.96%) | -$10,826,000 (5.70%) | -$11,480,000 (13.60%) | -$13,287,000 (-51.09%) |
Net Income to Non-Controlling Interests | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Net Income | -$7,150,000 (33.96%) | -$10,826,000 (5.70%) | -$11,480,000 (13.60%) | -$13,287,000 (-51.09%) |
Preferred Dividends Income Statement Impact | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Net Income Common Stock | -$7,150,000 (33.96%) | -$10,826,000 (5.70%) | -$11,480,000 (13.60%) | -$13,287,000 (-51.09%) |
Weighted Average Shares | $787,466 (240.15%) | $231,508 (83.32%) | $126,285 (6.30%) | $118,804 (179.70%) |
Weighted Average Shares Diluted | $787,466 (240.15%) | $231,508 (83.32%) | $126,285 (6.30%) | $118,804 (179.70%) |
Earning Before Interest & Taxes (EBIT) | -$7,150,000 (33.96%) | -$10,826,000 (5.70%) | -$11,480,000 (13.60%) | -$13,287,000 (-51.11%) |
Gross Profit | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Operating Income | -$7,387,000 (31.75%) | -$10,824,000 (5.57%) | -$11,462,000 (15.17%) | -$13,511,000 (-53.66%) |
PHIO Cash Flow Statement (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|
Net Cash Flow from Investing | $8,000 (260.00%) | -$5,000 (95.87%) | -$121,000 (-137.25%) | -$51,000 (-168.42%) |
Net Cash Flow from Financing | $3,996,000 (-46.09%) | $7,413,000 (28611.54%) | -$26,000 (-100.12%) | $21,722,000 (34.66%) |
Net Cash Flow from Operations | -$7,112,000 (33.84%) | -$10,749,000 (11.38%) | -$12,129,000 (-2.29%) | -$11,858,000 (-34.72%) |
Net Cash Flow / Change in Cash & Cash Equivalents | -$3,108,000 (6.97%) | -$3,341,000 (72.78%) | -$12,276,000 (-225.10%) | $9,813,000 (34.24%) |
Net Cash Flow - Business Acquisitions and Disposals | $9,000 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Net Cash Flow - Investment Acquisitions and Disposals | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Capital Expenditure | -$1,000 (80.00%) | -$5,000 (95.87%) | -$121,000 (-137.25%) | -$51,000 (-168.42%) |
Issuance (Repayment) of Debt Securities | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Issuance (Purchase) of Equity Shares | $4,001,000 (-46.23%) | $7,441,000 (0%) | $0 (0%) | $21,723,000 (36.37%) |
Payment of Dividends & Other Cash Distributions | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Effect of Exchange Rate Changes on Cash | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Share Based Compensation | $147,000 (-51.49%) | $303,000 (-26.81%) | $414,000 (-13.75%) | $480,000 (252.94%) |
Depreciation Amortization & Accretion | $35,000 (-80.98%) | $184,000 (-4.66%) | $193,000 (0.52%) | $192,000 (4.92%) |
PHIO Financial Metrics (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|
Gross Margin | - | - | - | - |
Profit Margin | - | - | - | - |
EBITDA Margin | - | - | - | - |
Return on Average Equity (ROAE) | -150.20% (-11.51%) | -134.70% (-78.41%) | -75.50% (-52.53%) | -49.50% (18.18%) |
Return on Average Assets (ROAA) | -120.40% (-13.69%) | -105.90% (-63.43%) | -64.80% (-44.64%) | -44.80% (12.84%) |
Return on Sales (ROS) | - | - | - | - |
Return on Invested Capital (ROIC) | 986.50% (11.26%) | 886.70% (-43.90%) | 1580.70% (-2.86%) | 1627.30% (-66.55%) |
Dividend Yield | 0% (0%) | 0% (0%) | 0% (0%) | 0% (0%) |
Price to Earnings Ratio (P/E) | -0.2 (-35.62%) | -0.15 (66.97%) | -0.44 (54.20%) | -0.96 (31.12%) |
Price to Sales Ratio (P/S) | - | - | - | - |
Price to Book Ratio (P/B) | 0.4 (67.50%) | 0.24 (-48.83%) | 0.47 (-23.99%) | 0.62 (-48.37%) |
Debt to Equity Ratio (D/E) | 0.21 (1.90%) | 0.21 (15.93%) | 0.18 (22.97%) | 0.15 (-29.19%) |
Earnings Per Share (EPS) | -9.08 (80.58%) | -46.76 (48.56%) | -90.91 (18.74%) | -111.87 (46.05%) |
Sales Per Share (SPS) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
Free Cash Flow Per Share (FCFPS) | -9.03 (80.55%) | -46.45 (52.11%) | -97 (3.23%) | -100.24 (51.73%) |
Book Value Per Share (BVPS) | 6 (-82.04%) | 33.39 (-61.09%) | 85.82 (-53.51%) | 184.61 (-39.76%) |
Tangible Assets Book Value Per Share (TABVPS) | 7.29 (-81.98%) | 40.45 (-60.14%) | 101.47 (-52.11%) | 211.86 (-42.82%) |
Enterprise Value Over EBIT (EV/EBIT) | 0 (0%) | 1 (0.00%) | 1 (0.00%) | 1 (0%) |
Enterprise Value Over EBITDA (EV/EBITDA) | 0.49 (-20.03%) | 0.61 (-25.03%) | 0.82 (-15.74%) | 0.97 (1100.00%) |
Asset Turnover | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
Current Ratio | 5.65 (-0.95%) | 5.71 (-11.12%) | 6.42 (-20.36%) | 8.06 (16.73%) |
Dividends | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Free Cash Flow (FCF) | -$7,113,000 (33.86%) | -$10,754,000 (12.21%) | -$12,250,000 (-2.86%) | -$11,909,000 (-35.01%) |
Enterprise Value (EV) | -$3,490,606 (46.54%) | -$6,529,980 (29.39%) | -$9,247,514 (27.36%) | -$12,730,308 (-1720.68%) |
Earnings Before Tax (EBT) | -$7,150,000 (33.96%) | -$10,826,000 (5.70%) | -$11,480,000 (13.60%) | -$13,287,000 (-51.09%) |
Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) | -$7,115,000 (33.14%) | -$10,642,000 (5.71%) | -$11,287,000 (13.81%) | -$13,095,000 (-52.09%) |
Invested Capital | -$659,000 (9.10%) | -$725,000 (7.76%) | -$786,000 (54.04%) | -$1,710,000 (-1468.81%) |
Working Capital | $4,721,000 (-38.59%) | $7,688,000 (-26.83%) | $10,507,000 (-51.49%) | $21,659,000 (67.02%) |
Tangible Asset Value | $5,738,000 (-38.72%) | $9,364,000 (-26.92%) | $12,814,000 (-49.09%) | $25,170,000 (59.92%) |
Market Capitalization | $1,899,394 (2.28%) | $1,857,020 (-63.48%) | $5,084,486 (-62.43%) | $13,534,692 (-12.96%) |
Average Equity | $4,761,500 (-40.77%) | $8,039,500 (-47.13%) | $15,204,750 (-43.38%) | $26,855,750 (84.61%) |
Average Assets | $5,938,000 (-41.94%) | $10,226,500 (-42.31%) | $17,727,750 (-40.22%) | $29,656,500 (73.19%) |
Invested Capital Average | -$724,750 (40.64%) | -$1,221,000 (-68.12%) | -$726,250 (11.05%) | -$816,500 (-351.73%) |
Shares | 1,055,219 (288.67%) | 271,494 (114.53%) | 126,555 (0.98%) | 125,321 (134.14%) |